heart failure
HeartBeat.bio and biotx.ai partner to develop new drugs for heart failure
July 7, 2025Mergers and Acquisitions, Research and Development AI, Cardiology, HeartBeat.bio, biotx.ai, heart failure
HeartBeat.bio and biotx.ai have entered a partnership to accelerate heart failure drug discovery by combining AI-driven genetics with human cardiac …
AnaCardio raises $19m in funding round for heart failure candidate
January 10, 2025Research and Development AnaCardio, Cardiology, cardiology, funding, heart failure
Swedish biopharmaceutical company AnaCardio has announced the completion of a Series A extension financing round that has raised $19m for …
AstraZeneca adds new heart failure target through collaboration with BenevolentAI
May 15, 2024Research and Development AstraZeneca, BenevolentAI, Cardiology, collaboration, heart failure
BenevolentAI has announced that AstraZeneca has added a novel heart failure target to its discovery portfolio following the two companies’ …
FDA approves Eko Health’s AI for heart failure detection
April 3, 2024Medical Communications Cardiology, Eko Health, FDA, heart failure, low ejection fraction
Eko Health has announced that the US Food and Drug Administration (FDA) has approved its Low Ejection Fraction (Low EF) …
AstraZeneca’s Forxiga approved in China for chronic heart failure treatment
August 18, 2023Medical Communications AstraZeneca, Cardiology, China, cardiovascular, heart failure
AstraZeneca has announced that Forxiga (dapagliflozin) has been approved in China to reduce the risk of cardiovascular death, hospitalisation for …
AstraZeneca’s Farxiga approved to reduce risk of cardiovascular death
May 9, 2023Medical Communications AstraZeneca, Cardiology, FDA, cvd, farxiga, heart failure
AstraZeneca has announced that the US Food and Drug Administration (FDA) has approved Farxiga to reduce the risk of cardiovascular …
FDA panel backs Novartis’ Entresto for different form of heart disease
December 16, 2020Research and Development FDA, Novartis, heart failure
Novartis’ heart failure drug Entresto has received recommendation from the FDA’s Cardiovascular and Renal Drugs Advisory Committee for use in …
Amgen and Cytokinetics’ drug falls short in heart failure despite hitting primary goal
October 9, 2020Medical Communications Amgen, cytokines, heart failure, pharma
New Phase 3 data has come to light on Amgen and Cytokinetics’ cardiac myosin activator therapy omecamtiv mecarbil fell short …
AZ’s Farxiga becomes first FDA-approved SGLT2 inhibitor for heart failure with reduced ejection fraction
May 6, 2020Research and Development, Sales and Marketing AstraZeneca, FDA, farxiga, heart failure
The FDA has moved to approve an oral tablet formulation of AstraZeneca’s Farxiga (dapagliflozin) to reduce the risk of cardiovascular …
Type 2 diabetes drug Rosiglitazone increases risk of heart problems
February 12, 2020Research and Development British Medical Journal, diabetes, heart failure, insulin, type 2, type 2 diabetes
A new study has given further evidence that rosiglitazone can contribute to risk of heart problems and heart failure. The …
Novartis’ Entresto narrowly misses Phase 3 goal in heart failure patients
September 2, 2019Research and Development, Sales and Marketing Entresto, Novartis, heart failure, pharma
New Phase 3 data for Novartis’ Entresto (sacubitril/valsartan) have been released, showing that the therapy narrowly missed its primary endpoint …
Novartis’ Entresto falls short at Phase 3 in heart failure with preserved ejection fraction
July 29, 2019Research and Development, Sales and Marketing Entresto, Novartis, heart failure, pharma
Novartis has been rocked by new Phase 3 data from a global trial into the efficacy of Entresto (sacubitril/valsartan), revealing …
Novartis’ Entresto tops enalapril in stabilised heart failure patients
November 13, 2018Manufacturing and Production, Research and Development Entresto, Novartis, cardiovascular, enalapril, heart failure, pharma
Novartis has declared new findings for Entresto (sacubitril/valsartan) at the American Heart Association’s (AHA) scientific sessions, showing that the drug proved …
AstraZeneca jettisons European heart drug rights for $210m
July 24, 2018Manufacturing and Production, Sales and Marketing AstraZeneca, Atacand, Cheplapharm, blood pressure, heart failure, pharma
AstraZeneca has announced its intention to hand over the European commercial rights to its heart failure and blood pressure treatment …
Bayer expands Broad Institute partnership to focus on heart failure
July 3, 2018Manufacturing and Production, Research and Development Bayer, broad institute, collaboration, heart failure, pharma
The Broad Institute of MIT and Harvard has expanded its partnership with Bayer through the launch of the Precision Cardiology …
